Evidence map›Paper›PMID 37649581›Full record

ArticlePNAS nexus2023

Conferring liver selectivity to a thyromimetic using a novel nanoparticle increases therapeutic efficacy in a diet-induced obesity animal model.

Ruiling Wu, Theeraphop Prachyathipsakul, Jiaming Zhuang, Hongxu Liu, Yanhui Han, Bin Liu, Shuai Gong, Jingyi Qiu, Siu Wong, Alexander Ribbe and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PNAS nexus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Actions of thyroid hormones and thyromimetics on the liver.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Ruiling WuDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Theeraphop PrachyathipsakulDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.ORCID https://orcid.org/0000-0002-7482-8199
Jiaming ZhuangDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Hongxu LiuDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.ORCID https://orcid.org/0000-0003-0076-1259
Yanhui HanDepartment of Food Science, University of Massachusetts, Amherst, MA 01003, USA.
Bin LiuDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Shuai GongDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Jingyi QiuThe Center for Bioactive Delivery, Institute for Applied Life Sciences, University of Massachusetts, Amherst, MA 01003, USA.
Siu WongMolecular and Cellular Biology Program, University of Massachusetts, Amherst, MA 01003, USA.
Alexander RibbeDepartment of Polymer Science and Engineering, University of Massachusetts, Amherst, MA 01003, USA.ORCID https://orcid.org/0000-0002-9924-3429
Jewel MedeirosDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Jayashree BhagabatiDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Jingjing GaoDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Peidong WuDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.
Ranit DuttaDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.ORCID https://orcid.org/0000-0002-8674-9826
Roman HerreraCyta Therapeutics, Inc., Lowell, MA 01852, USA.
Steve FaraciCyta Therapeutics, Inc., Lowell, MA 01852, USA.
Hang XiaoThe Center for Bioactive Delivery, Institute for Applied Life Sciences, University of Massachusetts, Amherst, MA 01003, USA.
S ThayumanavanDepartment of Chemistry, University of Massachusetts, Amherst, MA 01003, USA.ORCID https://orcid.org/0000-0002-6475-6726
University of Massachusetts Amherst · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimization of metabolic regulation is a promising solution for many pathologies, including obesity, dyslipidemia, type 2 diabetes, and inflammatory liver disease. Synthetic thyroid hormone mimics-based regulation of metabolic balance in the liver showed promise but was hampered by the low biocompatibility and harmful effects on the extrahepatic axis. In this work, we show that specifically directing the thyromimetic to the liver utilizing a nanogel-based carrier substantially increased therapeutic efficacy in a diet-induced obesity mouse model, evidenced by the near-complete reversal of body weight gain, liver weight and inflammation, and cholesterol levels with no alteration in the thyroxine (T4) / thyroid stimulating hormone (TSH) axis. Mechanistically, the drug acts by binding to thyroid hormone receptor β (TRβ), a ligand-inducible transcription factor that interacts with thyroid hormone response elements and modulates target gene expression. The reverse cholesterol transport (RCT) pathway is specifically implicated in the observed therapeutic effect. Overall, the study demonstrates a unique approach to restoring metabolic regulation impacting obesity and related metabolic dysfunctions.

Indexed as

anionic nanogelliver diseaseliver targetingmetabolic regulationthyroid hormone therapy

Identifiers

PMID37649581
PMCPMC10465086
OpenAlexW4386242413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.